We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen Submits Four-Year Phase 4 Study Protocol for FDA Approval
Biogen Submits Four-Year Phase 4 Study Protocol for FDA Approval
Biogen will complete its FDA-mandated phase 4 Aduhelm study in four years — less than half the time the agency allotted when it granted accelerated approved for the controversial antiamyloid antibody last year.